| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | BCL-LZH-4 | CTRPv2 | pan-cancer | AAC | 0.0095 | 0.9 |
| mRNA | KH-CB19 | CTRPv2 | pan-cancer | AAC | -0.0085 | 0.9 |
| mRNA | MLN2238 | CTRPv2 | pan-cancer | AAC | 0.0063 | 0.9 |
| mRNA | PHA-793887 | GDSC1000 | pan-cancer | AAC | -0.0047 | 0.9 |
| mRNA | BMS-509744 | GDSC1000 | pan-cancer | AAC | 0.0087 | 0.9 |
| mRNA | WZ4002 | CTRPv2 | pan-cancer | AAC | 0.0078 | 0.9 |
| mRNA | BRD-A02303741:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.0064 | 0.9 |
| mRNA | BRD-A05715709 | CTRPv2 | pan-cancer | AAC | 0.0097 | 0.9 |
| mRNA | Cyclopamine | GDSC1000 | pan-cancer | AAC | 0.0087 | 0.9 |
| mRNA | tubastatin A | CTRPv2 | pan-cancer | AAC | -0.0091 | 0.9 |